Advancements in the Management of R/R AML: ASH 2024 - Episode 11

Future Perspectives on Menin Inhibitors in Acute Leukemias

February 11, 2025

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO , James Blachly, MD, Aaron Goldberg, MD, PhD Memorial Sloan Kettering Cancer Center, Rami Komrokji, MD, Gabe Mannis, MD , Michael J. Thirman, MD

Panelists discuss preclinical findings on the potential role of menin inhibitors in relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL), the implications of p-MEF2C as a biomarker for reshaping the therapeutic landscape and integrating menin inhibitors such as revumenib into clinical practice, and what they anticipate learning from the upcoming presentation on menin inhibitor resistance, highlighting the role of MEN1 mutations in guiding treatment sequencing for MI-resistant acute leukemias.

EP. 1: Treatment Strategies for Relapsed/Refractory AML Patients

EP. 2: Treatment Goals and Unmet Needs in R/R AML

EP. 3: Navigating Challenges in Second- and Third-Line AML Therapy

EP. 4: Revumenib’s FDA Approval and Clinical Implications

EP. 5: Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

EP. 6: Adverse Event Management and Patient Safety With Revumenib

EP. 7: MRD Testing and the Role of Revumenib in Treatment Response

EP. 8: Integrating Revumenib Into Current R/R AML Treatment Paradigms

EP. 9: Genetic Testing and Molecular Profiling in AML

EP. 10: Emerging Combination Strategies and Preclinical Findings

Now Viewing

EP. 11: Future Perspectives on Menin Inhibitors in Acute Leukemias

EP. 12: Closing Perspectives on R/R AML Treatment Advances

Video content above is prompted by the following:

Dr. LeBlanc: Briefly comment on the preclinical findings presented regarding the potential role of menin inhibitors in R/R T-ALL. (Shimamoto, KK, et al. ASH 2024. Poster Abstract 1452, Session: 614 or pg. 19)

Dr. LeBlanc to ask GROUP: How might the identification of p-MEF2C as a biomarker reshape the therapeutic landscape for T-ALL, and what implications does this have for integrating menin inhibitors like such as revumenib into clinical practice?

Dr. LeBlanc to ask GROUP: Briefly comment on what you are looking forward to learning in the upcoming presentation, “Discerning the Landscape of Menin Inhibitor Resistance.” (Bourgeois, W, et al. ASH 2024. Oral Abstract 724, Session: 604 or pg. 21)

How can the identification of specific MEN1 mutations and their differential effects on various menin inhibitors inform treatment sequencing strategies and optimize outcomes for patients with MI-resistant acute leukemias?